Thermo Fisher Scientific (TMO) Short term Debt (2009 - 2026)

Thermo Fisher Scientific has disclosed Short term Debt across 18 years of filings, most recently posting $3.1 billion for Q1 2026.

• Quarterly Short term Debt rose 9.61% year-over-year to $3.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 9.61% YoY) and the FY2025 annual result came in at $3.5 billion, up 59.58% from the prior year.
• Short term Debt slipped to $3.1 billion in Q1 2026, from $3.5 billion in the prior quarter.
• Over five years, Short term Debt peaked at $6.1 billion in Q2 2023 and troughed at $1.0 billion in Q3 2022.
• A 5-year average of $3.5 billion and a median of $3.6 billion in 2023 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2022 — Short term Debt jumped 46550.0% — and 2025, when it tumbled 56.77%.
• Tracing TMO's Short term Debt over 5 years: stood at $5.6 billion in 2022, then sank by 35.31% to $3.6 billion in 2023, then plunged by 38.65% to $2.2 billion in 2024, then surged by 59.58% to $3.5 billion in 2025, then retreated by 12.54% to $3.1 billion in 2026.
• Business Quant data shows TMO's Short term Debt at $3.1 billion in Q1 2026, $3.5 billion in Q4 2025, and $3.8 billion in Q3 2025.